Key result
A high plasma TMAO level (>5.80 μmol/L) was independently associated with an increased risk of 6-month MACE in acute myocardial infarction patients (HR 2.45; 95% CI 1.38-4.35; P=.002).
Why the study?
The relationship of plasma TMAO with disease severity and short-term prognosis in AMI patients was not well established.
Are elevated plasma TMAO levels associated with increased disease severity and short-term MACE risk in patients with acute myocardial infarction?
Observational (n=90)
No
Are elevated plasma TMAO levels associated with increased disease severity and short-term MACE risk in patients with acute myocardial infarction?
Hazard Ratio: 2.45 (95% CI 1.38–4.35)
p-value: p=.002
Elevated plasma TMAO levels at admission are strongly correlated with coronary disease severity and independently predict short-term adverse cardiovascular events in patients with acute myocardial infarction.
OBJECTIVE: This study examined the relationship of plasma trimethylamine N-oxide (TMAO), a gut microbiota-derived metabolite, with both disease severity and short-term prognosis in acute myocardial infarction (AMI) patients. METHODS: This retrospective observational study was performed at a single center and comprised 60 AMI patients along with 30 controls with angiographically normal or near-normal coronary arteries (stenosis <20% in all major epicardial vessels). Plasma TMAO levels were measured at admission via high-performance liquid chromatography-tandem mass spectrometry. The severity of coronary artery disease was graded according to the Gensini score. Patients were followed up for 6 months after discharge, and the occurrence of major adverse cardiovascular events (MACEs) within this period was ascertained retrospectively from hospital electronic medical records and routine cardiology follow-up documentation. RESULTS: Compared to controls, AMI patients had significantly higher plasma TMAO levels (median 5.80 vs. 2.10 μmol/L, P < .001). Consistent with its elevation, TMAO demonstrated a strong positive correlation with the Gensini score (rs = 0.998, P < .001) and peak troponin I (rs = 0.996, P < .001). A high TMAO level (>5.80 μmol/L) was ndependently associated with an increased risk of 6-month MACE (hazard ratio = 2.45, 95% CI: 1.38-4.35, P = .002). Furthermore, incorporating TMAO into traditional clinical models enhanced their predictive performance, yielding a modest yet statistically significant improvement in the area under the curve from 0.880 to 0.884 (P = .012). CONCLUSION: Elevated plasma TMAO is associated with more severe coronary artery disease, greater myocardial injury, and worse short-term prognosis in AMI patients, offering incremental prognostic value beyond conventional risk factors.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) conducted an observational in Acute myocardial infarction (n=90). High plasma TMAO level (>5.80 μmol/L) vs. Lower TMAO level was evaluated on 6-month major adverse cardiovascular events (MACE) (HR 2.45, 95% CI 1.38-4.35, p=.002). A high plasma TMAO level (>5.80 μmol/L) was independently associated with an increased risk of 6-month MACE in acute myocardial infarction patients (HR 2.45; 95% CI 1.38-4.35; P=.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: